<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB03394</drugbank-id>
  <drugbank-id>EXPT02477</drugbank-id>
  <name>Heptaethylene glycol</name>
  <description/>
  <cas-number>5617-32-3</cas-number>
  <unii>ZBR3T82M2V</unii>
  <average-mass>326.3832</average-mass>
  <monoisotopic-mass>326.194067936</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as polyethylene glycols. These are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n&gt;=3).</description>
    <direct-parent>Polyethylene glycols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Ethers</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Polyethylene glycol</substituent>
    <substituent>Primary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">3,6,9,12,15,18-hexaoxaeicosane-1,20-diol</synonym>
    <synonym language="english" coder="">Heptaethylene glycol, Peg330</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1oxn</pdb-entry>
    <pdb-entry>1oxq</pdb-entry>
    <pdb-entry>1oy7</pdb-entry>
    <pdb-entry>1t0t</pdb-entry>
    <pdb-entry>1vg9</pdb-entry>
    <pdb-entry>1wma</pdb-entry>
    <pdb-entry>1y4l</pdb-entry>
    <pdb-entry>1zzm</pdb-entry>
    <pdb-entry>2aaw</pdb-entry>
    <pdb-entry>2afv</pdb-entry>
    <pdb-entry>2ajs</pdb-entry>
    <pdb-entry>2aoa</pdb-entry>
    <pdb-entry>2f1f</pdb-entry>
    <pdb-entry>2hr7</pdb-entry>
    <pdb-entry>2i02</pdb-entry>
    <pdb-entry>2iz0</pdb-entry>
    <pdb-entry>2iz1</pdb-entry>
    <pdb-entry>2vlf</pdb-entry>
    <pdb-entry>2vlh</pdb-entry>
    <pdb-entry>2y2u</pdb-entry>
    <pdb-entry>2ycp</pdb-entry>
    <pdb-entry>2yct</pdb-entry>
    <pdb-entry>2yhk</pdb-entry>
    <pdb-entry>3a9f</pdb-entry>
    <pdb-entry>3b1q</pdb-entry>
    <pdb-entry>3bhj</pdb-entry>
    <pdb-entry>3cc1</pdb-entry>
    <pdb-entry>3cmb</pdb-entry>
    <pdb-entry>3f7g</pdb-entry>
    <pdb-entry>3fd3</pdb-entry>
    <pdb-entry>3ffr</pdb-entry>
    <pdb-entry>3fkh</pdb-entry>
    <pdb-entry>3h4q</pdb-entry>
    <pdb-entry>3klt</pdb-entry>
    <pdb-entry>3qnl</pdb-entry>
    <pdb-entry>3r56</pdb-entry>
    <pdb-entry>3rjd</pdb-entry>
    <pdb-entry>3tgw</pdb-entry>
    <pdb-entry>3uto</pdb-entry>
    <pdb-entry>3zkk</pdb-entry>
    <pdb-entry>4bgu</pdb-entry>
    <pdb-entry>4ec4</pdb-entry>
    <pdb-entry>4g61</pdb-entry>
    <pdb-entry>4hs7</pdb-entry>
    <pdb-entry>4inn</pdb-entry>
    <pdb-entry>4kl9</pdb-entry>
    <pdb-entry>4kr5</pdb-entry>
    <pdb-entry>4kvj</pdb-entry>
    <pdb-entry>4mn3</pdb-entry>
    <pdb-entry>4n4d</pdb-entry>
    <pdb-entry>4pop</pdb-entry>
    <pdb-entry>4rlj</pdb-entry>
    <pdb-entry>4u6t</pdb-entry>
    <pdb-entry>4w8o</pdb-entry>
    <pdb-entry>4xjy</pdb-entry>
    <pdb-entry>4xvx</pdb-entry>
    <pdb-entry>4xwl</pdb-entry>
    <pdb-entry>4z5q</pdb-entry>
    <pdb-entry>4zcs</pdb-entry>
    <pdb-entry>5j81</pdb-entry>
    <pdb-entry>5l2v</pdb-entry>
    <pdb-entry>5l8i</pdb-entry>
    <pdb-entry>5l8n</pdb-entry>
    <pdb-entry>5lkj</pdb-entry>
    <pdb-entry>5nir</pdb-entry>
    <pdb-entry>5nqd</pdb-entry>
    <pdb-entry>5utu</pdb-entry>
    <pdb-entry>5xaw</pdb-entry>
    <pdb-entry>5zb2</pdb-entry>
    <pdb-entry>6aol</pdb-entry>
    <pdb-entry>6aom</pdb-entry>
    <pdb-entry>6asp</pdb-entry>
    <pdb-entry>6c5b</pdb-entry>
    <pdb-entry>6cj6</pdb-entry>
    <pdb-entry>6dur</pdb-entry>
    <pdb-entry>6dvx</pdb-entry>
    <pdb-entry>6dxy</pdb-entry>
    <pdb-entry>6dyt</pdb-entry>
    <pdb-entry>6dz5</pdb-entry>
    <pdb-entry>6ecg</pdb-entry>
    <pdb-entry>6f9v</pdb-entry>
    <pdb-entry>6fuv</pdb-entry>
    <pdb-entry>6h2y</pdb-entry>
    <pdb-entry>6h7d</pdb-entry>
    <pdb-entry>6hos</pdb-entry>
    <pdb-entry>6i7i</pdb-entry>
    <pdb-entry>6ju1</pdb-entry>
    <pdb-entry>6mls</pdb-entry>
    <pdb-entry>6mme</pdb-entry>
    <pdb-entry>6mo3</pdb-entry>
    <pdb-entry>6mpd</pdb-entry>
    <pdb-entry>6mqq</pdb-entry>
    <pdb-entry>6mxt</pdb-entry>
    <pdb-entry>6ol9</pdb-entry>
    <pdb-entry>6qf3</pdb-entry>
  </pdb-entries>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Peginesatide can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.65</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.55e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3,6,9,12,15,18-hexaoxaicosane-1,20-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>cycloguanil pamoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>326.3832</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>326.194067936</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OCCOCCOCCOCCOCCOCCOCCO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H30O8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H30O8/c15-1-3-17-5-7-19-9-11-21-13-14-22-12-10-20-8-6-18-4-2-16/h15-16H,1-14H2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XPJRQAIZZQMSCM-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>95.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>80.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>37.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>14.82</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>44748</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>79718</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46504978</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>72017</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>P33</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0003074</id>
      <name>Carbonyl reductase [NADPH] 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16152" source="Swiss-Prot">
        <name>Carbonyl reductase [NADPH] 1</name>
        <general-function>Prostaglandin-e2 9-reductase activity</general-function>
        <specific-function>NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.</specific-function>
        <gene-name>CBR1</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.49</theoretical-pi>
        <molecular-weight>30374.73</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1548</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CBR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J04056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16152</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CBR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.1.1.184</synonym>
          <synonym>15-hydroxyprostaglandin dehydrogenase [NADP(+)]</synonym>
          <synonym>CBR</synonym>
          <synonym>CRN</synonym>
          <synonym>NADPH-dependent carbonyl reductase 1</synonym>
          <synonym>Prostaglandin 9-ketoreductase</synonym>
          <synonym>Prostaglandin-E(2) 9-reductase</synonym>
          <synonym>SDR21C1</synonym>
          <synonym>Short chain dehydrogenase/reductase family 21C member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006005|Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012150|Carbonyl reductase [NADPH] 1 (CBR1)
ATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCC
ATCGTGCGCGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTG
ACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCAC
CAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAG
TACGGGGGCCTGGACGTGCTGGTCAACAACGCGGGCATCGCCTTCAAGGTTGCTGATCCC
ACACCCTTTCATATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGAT
GTGTGCACAGAATTACTCCCTCTAATAAAACCCCAAGCATCCTGCGTACTGTCTGCATGG
TCATGCCTCTCCCAAAATCCTTCAGGAGGAAAGTCCAAGCCCTTAGCATGGTTCACAGAG
ATGTCCATAATCTGCCGCTGCTTAACTCTGGGCCCATTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00106</identifier>
            <name>adh_short</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>15-hydroxyprostaglandin dehydrogenase (NADP+) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carbonyl reductase (NADPH) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin-E2 9-reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclooxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin K metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>